Mitapivat
AG348-C-024
Phase 1 small_molecule completed
Quick answer
Mitapivat for Moderate Hepatic Impairment is a Phase 1 program (small_molecule) at AGIOS PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AGIOS PHARMACEUTICALS, INC.
- Indication
- Moderate Hepatic Impairment
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed